ArticleImmunological reviews2017
Introduction to checkpoint inhibitors and cancer immunotherapy.
Article in Immunological reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.Nature communications · 2024Pooled it
- Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis.JCO precision oncology · 2021Pooled it
- Pooled it
- Targeting CD6 in solid tumors: safety, early efficacy, and mechanistic insights from a proof-of-concept trial of itolizumab.Journal for immunotherapy of cancer · 2026Article
- Deep Durable Response in Metastatic Hepatocellular Carcinoma After Early Discontinuation of Atezolizumab-Bevacizumab.ACG case reports journal · 2026Article
- Genetic variability of immune checkpoints in asbestos-related diseases.Radiology and oncology · 2026Article
- A human tumor-immune organoid model of glioblastoma.Cell reports · 2026Article
- Exploiting signal transduction pathways for cancer therapy: insights from natural products in preclinical models.Frontiers in pharmacology · 2026Review
- Efficacy of anti-LAG3 and anti-PD-1 combination checkpoint inhibitor therapy against head and neck squamous cell carcinoma in a genetically engineered mouse model.Oncoimmunology · 2025Article
- IL-15 Complexes Combined with PD-1 Blockade Affect Immune Cell Distribution, Localization, and Immune Signatures in Regressing Versus Non-Regressing Metastatic Breast Tumors.International journal of molecular sciences · 2025Article
- A Human Tumor-Immune Organoid Model of Glioblastoma.bioRxiv : the preprint server for biology · 2025Article
- Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report.Journal of liver cancer · 2025Article
- Bacterial-Mediated In Situ Engineering of Tumour-Associated Macrophages for Cancer Immunotherapy.Cancers · 2025Review
- Evaluating the impact of immune checkpoint inhibitors on liver steatosis and function: a retrospective cohort analysis.Frontiers in oncology · 2025Article
- Immune Checkpoint Inhibitor Associated Rheumatoid Arthritis.Current rheumatology reports · 2024Review
- Modulation of the tumor microenvironment in non-muscle-invasive bladder cancer by OncoTherad® (MRB-CFI-1) nanoimmunotherapy: effects on tumor-associated macrophages, tumor-infiltrating lymphocytes, and monoamine oxidases.Medical oncology (Northwood, London, England) · 2024Article
- The Immune Resistance Signature of Acute Myeloid Leukemia and Current Immunotherapy Strategies.Cancers · 2024Review
- Development of small molecule drugs targeting immune checkpoints.Cancer biology & medicine · 2024Review
- Sirpα on tumor-associated myeloid cells restrains antitumor immunity in colorectal cancer independent of its interaction with CD47.Nature cancer · 2024Article
- The influence of immune checkpoint blockade on the outcomes of allogeneic hematopoietic stem cell transplantation.Frontiers in immunology · 2024Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.